Virus cocktail takes on superbug pneumonia in ventilator patients
NCT ID NCT07202234
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a cocktail of viruses called bacteriophages can treat ventilator-associated pneumonia caused by multidrug-resistant bacteria. 248 adults on ventilators will receive either the phage cocktail or a placebo via nebulizer. The goal is to see if the treatment improves infection clearance and survival.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- bacteriophage cocktail
- What this could lead to
- If it works, this could provide a new treatment option for hard-to-treat pneumonia caused by drug-resistant bacteria.
- What could go wrong
- This is an early-stage trial with no phase designation, so results are uncertain. The therapy may not improve outcomes or could cause side effects like allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 248 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2025
An estimate. Start dates often move.
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Diagnosed with ventilator-associated pneumonia (VAP); 2. Identified infection with MDR Klebsiella pneumoniae, Acinetobacter baumannii, or Pseudomonas aeruginosa via MROSE evaluation and antimicrobial susceptibility testing (AST) from this or other tertiary hospitals; 3. Aged 18 to 85 years; 4. Written informed consent obtained from the patient or legal guardian. Exclusion Criteria: 1. Pregnant or breastfeeding women; 2. FiO₂ ≥ 70% or PEEP ≥ 15 cmH₂O; 3. Hemodynamic instability (vasopressor dose increased by ≥30% in the last 6 hours or norepinephrine \> 0.5 μg/kg/min); 4. Known allergy to phage components.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Vap - ventilator associated pneumonia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.